These receptors stimulate hormones that control blood sugar levels and reduce appetite, triggering weight loss
Al-Jafari M, Alrosan S, Alkhawaldeh IM, Zein Eddin S, Abu-Jeyyab M, Zuaiter SN
Careful follow-up of weight and height in pediatric patients ages 7 to 10 years who were randomized to either methylphenidate or non-medication treatment groups over 14 months, as well as in naturalistic subgroups of newly methylphenidate-treated and non-medication treated pediatric patients over 36 months (to the ages of 10 to 13 years), suggests that consistently medicated pediatric patients ages 7 to 13 years (i.e., treatment for 7 days per week throughout the year) have a temporary slowing in growth rate (on average, a total of about 2 cm less growth in height and 2.7 kg less growth in weight over 3 years), without evidence of growth rebound during this period of development
MedicalDaily will track approvals, Phase 3 results, and insurance coverage changes across the GLP-1 pipeline as they develop
Bottom line GLP-1 drugs can be effective tools for weight loss and blood sugar control